Trial Profile
Bevacizumab versus combined bevacizumab and triamcinolone for refractory diabetic macular edema; a randomized clinical trial
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 16 Jan 2017
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Triamcinolone (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- 15 Oct 2006 New trial record.